Nordic Nanovector updates on Clinical Trial Applications for Archer-1 and PARADIGME Trials in Norway
Oslo, Norway, 25 May 2018 Nordic Nanovector ASA (OSE: NANO) has received feedback from the Regional Committees for Medical and Health Research Ethics (REK) in Norway with regard to the Clinical Trial Application (CTA) for the Archer-1 Phase 1b trial with Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab in second-line follicular lymphoma patients. Feedback from REK has been received following a review of the CTA for Archer-1, which took place on 26 April. The company and the lead investigator for the trial, Dr Arne Kolstad, senior consultant in medical oncology